- Home
- STSS vs ADTX Comparison
STSS vs ADTX Comparison
Compare STSS & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- ADTX
- Stock Information
- Founded
- STSS 2017
- ADTX 2017
- Country
- STSS United States
- ADTX United States
- Employees
- STSS N/A
- ADTX N/A
- Industry
- STSS Medical/Dental Instruments
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- ADTX Health Care
- Exchange
- STSS Nasdaq
- ADTX Nasdaq
- Market Cap
- STSS 5.1M
- ADTX 4.9M
- IPO Year
- STSS 2022
- ADTX 2020
- Fundamental
- Price
- STSS $9.47
- ADTX $1.03
- Analyst Decision
- STSS
- ADTX
- Analyst Count
- STSS 0
- ADTX 0
- Target Price
- STSS N/A
- ADTX N/A
- AVG Volume (30 Days)
- STSS 3.4M
- ADTX 192.8K
- Earning Date
- STSS 08-13-2025
- ADTX 08-14-2025
- Dividend Yield
- STSS N/A
- ADTX N/A
- EPS Growth
- STSS N/A
- ADTX N/A
- EPS
- STSS N/A
- ADTX N/A
- Revenue
- STSS $222,722.00
- ADTX $12,051.00
- Revenue This Year
- STSS N/A
- ADTX $15,768.94
- Revenue Next Year
- STSS N/A
- ADTX N/A
- P/E Ratio
- STSS N/A
- ADTX N/A
- Revenue Growth
- STSS N/A
- ADTX N/A
- 52 Week Low
- STSS $3.36
- ADTX $0.81
- 52 Week High
- STSS $1,840.74
- ADTX $5,161.00
- Technical
- Relative Strength Index (RSI)
- STSS 51.87
- ADTX 48.16
- Support Level
- STSS $8.75
- ADTX $0.89
- Resistance Level
- STSS $10.93
- ADTX $1.11
- Average True Range (ATR)
- STSS 2.53
- ADTX 0.08
- MACD
- STSS -0.35
- ADTX 0.01
- Stochastic Oscillator
- STSS 8.74
- ADTX 58.16
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.